4.5 Article

International consensus on diagnosis and management of Dravet syndrome

期刊

EPILEPSIA
卷 63, 期 7, 页码 1761-1777

出版社

WILEY
DOI: 10.1111/epi.17274

关键词

cannabidiol; developmental and epileptic encephalopathy; disease-modifying treatment; fenfluramine; SCN1A; stiripentol

资金

  1. Dravet Syndrome Foundation

向作者/读者索取更多资源

This study aimed to reach a consensus on the diagnosis and management of Dravet syndrome (DS) by consulting experienced physicians and caregivers. The study summarized the current literature and obtained opinions from an expert panel on the diagnosis and management of DS. The results showed that there was consensus on the diagnosis and treatment of DS, but there was disagreement on disease-modifying therapies.
Objective This study was undertaken to gain consensus from experienced physicians and caregivers regarding optimal diagnosis and management of Dravet syndrome (DS), in the context of recently approved, DS-specific therapies and emerging disease-modifying treatments. Methods A core working group was convened consisting of six physicians with recognized expertise in DS and two representatives of the Dravet Syndrome Foundation. This core group summarized the current literature (focused on clinical presentation, comorbidities, maintenance and rescue therapies, and evolving disease-modifying therapies) and nominated the 31-member expert panel (ensuring international representation), which participated in two rounds of a Delphi process to gain consensus on diagnosis and management of DS. Results There was strong consensus that infants 2-15 months old, presenting with either a first prolonged hemiclonic seizure or first convulsive status epilepticus with fever or following vaccination, in the absence of another cause, should undergo genetic testing for DS. Panelists agreed on evolution of specific comorbidities with time, but less agreement was achieved on optimal management. There was also agreement on appropriate first- to third-line maintenance therapies, which included the newly approved agents. Whereas there was agreement for recommendation of disease-modifying therapies, if they are proven safe and efficacious for seizures and/or reduction of comorbidities, there was less consensus for when these should be started, with caregivers being more conservative than physicians. Significance This International DS Consensus, informed by both experienced global caregiver and physician voices, provides a strong overview of the impact of DS, therapeutic goals and optimal management strategies incorporating the recent therapeutic advances in DS, and evolving disease-modifying therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据